The pharmacological treatment for uremic restless legs syndrome: evidence-based review.
Identifieur interne : 001802 ( PubMed/Corpus ); précédent : 001801; suivant : 001803The pharmacological treatment for uremic restless legs syndrome: evidence-based review.
Auteurs : Márcio Moysés De Oliveira ; Cristiane Fiquene Conti ; Juliana Spelta Valbuza ; Luciane Bizari Coin De Carvalho ; Gilmar Fernandes Do PradoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- complications : Restless Legs Syndrome.
- drug therapy : Restless Legs Syndrome, Uremia.
- etiology : Uremia.
- statistics & numerical data : Databases, Factual.
- Cross-Over Studies, Double-Blind Method, Evidence-Based Medicine, Humans, Randomized Controlled Trials as Topic.
Abstract
Restless legs syndrome (RLS) is a common and often misdiagnosed entity among the general population and it may be more common among dialysis patients, with an estimated prevalence of 6.6 to 21.5%. The treatment for uremic RLS has been controversial and therefore a systematic synthesis of the evidence is needed in order to evaluate the effectiveness and safety of treatments for uremic RLS. This was a systematic review of randomized or quasi-randomized double-blind trials on treatments for uremic RLS. The outcomes considered were relief of RLS symptoms marked on a validated scale, subjective sleep quality, sleep quality measured using night polysomnography and actigraphy, quality of life measured subjectively, and adverse events associated with these treatments. Six eligible clinical trials were included. The results from subjective analyses in these studies were divergent, although objective analyses in one trial showed that there was a statistically significant improvement in periodic leg movement while asleep in the treatment group. No combined analysis (meta-analysis) was performed. The most common adverse event seen was gastrointestinal symptoms. Only a few therapeutic trials on patients with uremia with RLS have been published, and there is insufficient scientific evidence to favor any specific therapeutic regimen for uremic-associated RLS. Therapy using levodopa, dopaminergic agonists, anticonvulsants, and clonidine tend to be effective, but further studies are needed.
DOI: 10.1002/mds.22955
PubMed: 20544816
Links to Exploration step
pubmed:20544816Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The pharmacological treatment for uremic restless legs syndrome: evidence-based review.</title><author><name sortKey="De Oliveira, Marcio Moyses" sort="De Oliveira, Marcio Moyses" uniqKey="De Oliveira M" first="Márcio Moysés" last="De Oliveira">Márcio Moysés De Oliveira</name><affiliation><nlm:affiliation>Department of Emergency Medicine and Evidence Based Medicine, Universidade Federal de São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Conti, Cristiane Fiquene" sort="Conti, Cristiane Fiquene" uniqKey="Conti C" first="Cristiane Fiquene" last="Conti">Cristiane Fiquene Conti</name></author><author><name sortKey="Valbuza, Juliana Spelta" sort="Valbuza, Juliana Spelta" uniqKey="Valbuza J" first="Juliana Spelta" last="Valbuza">Juliana Spelta Valbuza</name></author><author><name sortKey="De Carvalho, Luciane Bizari Coin" sort="De Carvalho, Luciane Bizari Coin" uniqKey="De Carvalho L" first="Luciane Bizari Coin" last="De Carvalho">Luciane Bizari Coin De Carvalho</name></author><author><name sortKey="Do Prado, Gilmar Fernandes" sort="Do Prado, Gilmar Fernandes" uniqKey="Do Prado G" first="Gilmar Fernandes" last="Do Prado">Gilmar Fernandes Do Prado</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.22955</idno><idno type="RBID">pubmed:20544816</idno><idno type="pmid">20544816</idno><idno type="wicri:Area/PubMed/Corpus">001802</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The pharmacological treatment for uremic restless legs syndrome: evidence-based review.</title><author><name sortKey="De Oliveira, Marcio Moyses" sort="De Oliveira, Marcio Moyses" uniqKey="De Oliveira M" first="Márcio Moysés" last="De Oliveira">Márcio Moysés De Oliveira</name><affiliation><nlm:affiliation>Department of Emergency Medicine and Evidence Based Medicine, Universidade Federal de São Paulo, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Conti, Cristiane Fiquene" sort="Conti, Cristiane Fiquene" uniqKey="Conti C" first="Cristiane Fiquene" last="Conti">Cristiane Fiquene Conti</name></author><author><name sortKey="Valbuza, Juliana Spelta" sort="Valbuza, Juliana Spelta" uniqKey="Valbuza J" first="Juliana Spelta" last="Valbuza">Juliana Spelta Valbuza</name></author><author><name sortKey="De Carvalho, Luciane Bizari Coin" sort="De Carvalho, Luciane Bizari Coin" uniqKey="De Carvalho L" first="Luciane Bizari Coin" last="De Carvalho">Luciane Bizari Coin De Carvalho</name></author><author><name sortKey="Do Prado, Gilmar Fernandes" sort="Do Prado, Gilmar Fernandes" uniqKey="Do Prado G" first="Gilmar Fernandes" last="Do Prado">Gilmar Fernandes Do Prado</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cross-Over Studies</term><term>Databases, Factual (statistics & numerical data)</term><term>Double-Blind Method</term><term>Evidence-Based Medicine</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Restless Legs Syndrome (complications)</term><term>Restless Legs Syndrome (drug therapy)</term><term>Uremia (drug therapy)</term><term>Uremia (etiology)</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term><term>Uremia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Uremia</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Evidence-Based Medicine</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Restless legs syndrome (RLS) is a common and often misdiagnosed entity among the general population and it may be more common among dialysis patients, with an estimated prevalence of 6.6 to 21.5%. The treatment for uremic RLS has been controversial and therefore a systematic synthesis of the evidence is needed in order to evaluate the effectiveness and safety of treatments for uremic RLS. This was a systematic review of randomized or quasi-randomized double-blind trials on treatments for uremic RLS. The outcomes considered were relief of RLS symptoms marked on a validated scale, subjective sleep quality, sleep quality measured using night polysomnography and actigraphy, quality of life measured subjectively, and adverse events associated with these treatments. Six eligible clinical trials were included. The results from subjective analyses in these studies were divergent, although objective analyses in one trial showed that there was a statistically significant improvement in periodic leg movement while asleep in the treatment group. No combined analysis (meta-analysis) was performed. The most common adverse event seen was gastrointestinal symptoms. Only a few therapeutic trials on patients with uremia with RLS have been published, and there is insufficient scientific evidence to favor any specific therapeutic regimen for uremic-associated RLS. Therapy using levodopa, dopaminergic agonists, anticonvulsants, and clonidine tend to be effective, but further studies are needed.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20544816</PMID><DateCreated><Year>2010</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>2010</Year><Month>12</Month><Day>02</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The pharmacological treatment for uremic restless legs syndrome: evidence-based review.</ArticleTitle><Pagination><MedlinePgn>1335-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22955</ELocationID><Abstract><AbstractText>Restless legs syndrome (RLS) is a common and often misdiagnosed entity among the general population and it may be more common among dialysis patients, with an estimated prevalence of 6.6 to 21.5%. The treatment for uremic RLS has been controversial and therefore a systematic synthesis of the evidence is needed in order to evaluate the effectiveness and safety of treatments for uremic RLS. This was a systematic review of randomized or quasi-randomized double-blind trials on treatments for uremic RLS. The outcomes considered were relief of RLS symptoms marked on a validated scale, subjective sleep quality, sleep quality measured using night polysomnography and actigraphy, quality of life measured subjectively, and adverse events associated with these treatments. Six eligible clinical trials were included. The results from subjective analyses in these studies were divergent, although objective analyses in one trial showed that there was a statistically significant improvement in periodic leg movement while asleep in the treatment group. No combined analysis (meta-analysis) was performed. The most common adverse event seen was gastrointestinal symptoms. Only a few therapeutic trials on patients with uremia with RLS have been published, and there is insufficient scientific evidence to favor any specific therapeutic regimen for uremic-associated RLS. Therapy using levodopa, dopaminergic agonists, anticonvulsants, and clonidine tend to be effective, but further studies are needed.</AbstractText><CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Márcio Moysés</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine and Evidence Based Medicine, Universidade Federal de São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Cristiane Fiquene</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Valbuza</LastName><ForeName>Juliana Spelta</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Luciane Bizari Coin</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>do Prado</LastName><ForeName>Gilmar Fernandes</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016208">Databases, Factual</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D019317">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012148">Restless Legs Syndrome</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014511">Uremia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22955</ArticleId><ArticleId IdType="pubmed">20544816</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001802 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001802 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20544816
|texte= The pharmacological treatment for uremic restless legs syndrome: evidence-based review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20544816" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |